The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exomes and transcriptomes to reveal actionable findings in patients with negative-targeted panel sequencing.
 
Eric Y. Zhao
No Relationships to Disclose
 
Jonathon Torchia
No Relationships to Disclose
 
Alexander Fortuna
No Relationships to Disclose
 
Dax Torti
No Relationships to Disclose
 
Celeste Yu
No Relationships to Disclose
 
Elizabeth Shah
No Relationships to Disclose
 
Aoife McCarthy
No Relationships to Disclose
 
Tracy Stockley
No Relationships to Disclose
 
Peter Sabatini
No Relationships to Disclose
 
John Bartlett
Honoraria - bioTheranostics; NanoString Technologies; Oncology Education
Consulting or Advisory Role - BioNTech; bioTheranostics; Insight Genetics; oncoXchange; Pfizer; RNA Diagnostics
Research Funding - Agendia; bioTheranostics; Genoptix; NanoString Technologies; Stratifyer GmbH; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - John Bartlett currently has 5 pending patents: 1. Jan 2017: Methods and Devices for Predicting Anthracycline Treatment Efficacy, US utility – 15/325,472; EPO – 15822898.1; Canada – not yet assigned 2. Jan 2017: Systems, Devices and Methods for Constructi (Inst)
Travel, Accommodations, Expenses - bioTheranostics; NanoString Technologies
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Arvinas; AstraZeneca/MedImmune; GlaxoSmithKline; Loxo; Merck; Mirati Therapeutics; MorphoSys; Navire; Oncorus; Roche; Seagen; Symphogen; Treadwell Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); SERVIER (Inst); SignalChem (Inst)
 
Trevor John Pugh
Honoraria - Chrysalis Biomedical Advisors; Merck; Prosigna
Consulting or Advisory Role - DynaCare
Research Funding - Boehringer Ingelheim (Inst)
Patents, Royalties, Other Intellectual Property - Combined hybrid-capture DNA sequencing for disease detection; Hybrid-capture sequencing for dete rmining immune cell clonality